Andrew Cooper
Stock Analyst at Raymond James
(2.32)
# 2,426
Out of 5,182 analysts
130
Total ratings
40.62%
Success rate
-0.43%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $24.24 | +85.64% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $84.64 | +12.24% | 4 | Oct 24, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $7.86 | +103.56% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $59.84 | +30.35% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $83.09 | -26.59% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $85.18 | +35.01% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $470.22 | +13.78% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $4.84 | +106.61% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $15.30 | +63.40% | 2 | May 5, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $195.02 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $178.98 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.91 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $200.17 | -57.54% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $12.02 | +532.28% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.57 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.02 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.43 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.01 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $24.24
Upside: +85.64%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $84.64
Upside: +12.24%
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $7.86
Upside: +103.56%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $59.84
Upside: +30.35%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $83.09
Upside: -26.59%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $85.18
Upside: +35.01%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $470.22
Upside: +13.78%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $4.84
Upside: +106.61%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $15.30
Upside: +63.40%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $195.02
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $178.98
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $21.91
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $200.17
Upside: -57.54%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $12.02
Upside: +532.28%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.57
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.02
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.43
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.01
Upside: -